---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027313"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2026-08-12T20:09:51+00:00"
generated_at: "2026-08-12T20:12:03.897497+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24

## Summary
- YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.
- GAAP net income $13.2M ($0.18/sh) vs $56.1M ($0.78) in Q1; non-GAAP adjusted net income $1.8M ($0.02) vs -$17.1M ($0.24).
- Cash and short-term investments $132.0M at June 30, 2026; Q2 operating cash flow $4.1M.
- In July, repurchased $30.5M principal of 2029 notes for $60.2M, cutting outstanding to $40.3M and conversion shares from ~11.4M to 6.5M.
- CHMP negative opinion on narsoplimab MAA for TA-TMA in June; re-examination requested. J-code effective July 1, NTAP effective Oct 1.

## SEC filing metadata
- accession: 0001437749-26-027313
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2026-08-12T20:09:51+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/0001437749-26-027313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/omer20260521_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027313
- JSON: https://secwatch.observer/filing/0001437749-26-027313.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.